Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 954,229 shares of RXRX, which is worth approximately $4.48 Million. The most recent transaction as insider was on Aug 26, 2025, when has been sold 100,000 shares (Class A Common Stock) at a price of $4.84 per share, resulting in proceeds of $484,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 954K

11.75% 3M change

25.12% 12M change

Total Value Held $4.48 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 26 2025	SELL Open market or private sale	$484,000 $4.84 p/Share	100,000 Reduced 9.49%	954,229 Class A Common Stock
Aug 26 2025	BUY Conversion of derivative security	-	100,000 Added 8.66%	1,054,229 Class A Common Stock
Aug 15 2025	SELL Payment of exercise price or tax liability	$227,799 $5.64 p/Share	40,390 Reduced 4.06%	954,229 Class A Common Stock
Aug 11 2025	SELL Bona fide gift	-	10,000 Reduced 1.0%	994,619 Class A Common Stock
Aug 11 2025	SELL Open market or private sale	$2,641,584 $5.28 p/Share	500,300 Reduced 33.24%	1,004,619 Class A Common Stock
Aug 11 2025	BUY Conversion of derivative security	-	423,666 Added 21.97%	1,504,919 Class A Common Stock
May 15 2025	SELL Payment of exercise price or tax liability	$153,837 $4.25 p/Share	36,197 Reduced 3.24%	1,081,253 Class A Common Stock
Mar 27 2025	SELL Open market or private sale	$836,986 $6.04 p/Share	138,574 Reduced 11.03%	1,117,450 Class A Common Stock
Mar 06 2025	SELL Open market or private sale	$127,400 $6.37 p/Share	20,000 Reduced 1.57%	1,256,024 Class A Common Stock
Mar 06 2025	BUY Conversion of derivative security	-	20,000 Added 1.54%	1,276,024 Class A Common Stock
Mar 05 2025	SELL Open market or private sale	$131,600 $6.58 p/Share	20,000 Reduced 1.57%	1,256,024 Class A Common Stock
Mar 05 2025	BUY Conversion of derivative security	-	20,000 Added 1.54%	1,276,024 Class A Common Stock
Feb 18 2025	SELL Payment of exercise price or tax liability	$182,284 $10.64 p/Share	17,132 Reduced 1.35%	1,256,024 Class A Common Stock
Feb 06 2025	SELL Open market or private sale	$162,399 $8.12 p/Share	20,000 Reduced 1.55%	1,273,156 Class A Common Stock
Feb 06 2025	BUY Conversion of derivative security	-	20,000 Added 1.52%	1,293,156 Class A Common Stock
Feb 05 2025	SELL Open market or private sale	$153,600 $7.68 p/Share	20,000 Reduced 1.55%	1,273,156 Class A Common Stock
Feb 05 2025	BUY Conversion of derivative security	-	20,000 Added 1.52%	1,293,156 Class A Common Stock
Feb 03 2025	SELL Payment of exercise price or tax liability	$40,375 $7.25 p/Share	5,569 Reduced 0.44%	1,273,156 Class A Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	542,092 Added 29.77%	1,278,725 Class A Common Stock
Jan 10 2025	SELL Open market or private sale	$141,000 $7.05 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Jan 10 2025	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock
Jan 08 2025	SELL Open market or private sale	$146,200 $7.31 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Jan 08 2025	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock
Dec 05 2024	SELL Open market or private sale	$142,400 $7.12 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Dec 05 2024	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account